Oncodrone receives €2.5m Eurostars grant

Published: 26-Aug-2015

For the development of a treatment for prostate cancer


Oncodrone, a developer of cancer drugs based in Nijmegen, the Netherlands, has received a €2.5m Eurostars grant for the development of a treatment for prostate cancer.

The grant will enable the Oncodrone to progress its lead product candidate, OCD155, through pre-clinical development towards clinical trials and to unravel further the mechanism-of-action. This will be handled by a Dutch-Danish-German-Swiss consortium, including the Dutch partners Radboud University Medical Centre (UMC) and Leiden UMC.

OCD155 halts tumour progression by blocking Epethelial to Mesenchymal Transition (EMT) in cancers. It has been shown in in vivo laboratory experiments to reduce the ability of tumours to spread, reduce the tumour burden and treat advanced stages of disease. Once proven to be safe to use, the drug can be tested in patients with metastasised carcinomas including prostate, breast, lung and pancreatic cancer.

Henk Viëtor, CEO of Oncodrone, said: 'I’m delighted about this crucial grant, which allows us to further develop our novel approach to treating prostate cancer towards testing in humans.'

You may also like